

Building bridges with Africa and the Middle East:
the role of Gruppo San Donato and GK Investment Holding Group in the future of healthcare

Covid-19 medical research



**Gruppo
San Donato**



In collaboration with




The European House
Ambrosetti


After the first outbreak in Wuhan, Italy became the main hotspot of the Covid-19 epidemic

In a matter of days, intensive care units were flooded with patients with an **unknown disease** for which there was **no cure** and **limited diagnostic capacity**

Italy Covid-19 lab tested cases, Number of infections since patient 1




Source: The European House – Ambrosetti on Italian Ministry of Health data, 2020.




*Illustration of
the ultrastructure
of the Covid-19 virus*

In that period, Italy faced a faster surge of infections and mortality compared to other EU countries

Covid-19 lab tested cases,
Number of infections since patient 1, main EU countries



Italy Covid-19 deaths,
Number of deaths since the first one



Source: The European House – Ambrosetti on Worldometer data, 2020.

Lombardy, the heart of the Italian economy, became one of the world's hardest hit regions



- As one of the major university and research hospitals in the region, this tragic emergency positioned us **at the frontline in the scientific battle against Covid-19**, providing us with a scientific edge to develop treatment and diagnostic capacity



- We therefore launched our **Program Project Covid-19**, a multidisciplinary project to fill the scientific gap surrounding Covid-19 and Sars-Cov-2

Source: The European House – Ambrosetti on Italian Ministry of Health and World Bank data, 2020.

	Number of Covid-19 cases	Number of Covid-19 deaths
Italy	414,241	36,543
Lombardy	126,769 30,4%	17,078 46,7%

Lombardy key figures

- 10.06 million people** (16.6% of the total national population)
- €366 billion in 2019 (**21.8% of Italy's GDP**)



Program Project Covid-19 aimed at rapidly developing scientific knowledge and capacity with multiple goals



Program Project Covid-19 goals



Develop **evidence-based knowledge** to both diagnose and treat Covid-19 infections

Improve our understanding of Covid-19 pathogenesis and Sars-Cov-2 characteristics, thanks to data collected from patients and to the analysis of biobanked samples

Create **BSL-2 and BSL-3 structures** to safely handle dangerous viruses and carry out projects to develop innovative antiviral treatments

The immediate goal was to develop treatment capacity to face the Covid-19 medical emergency...



Given the short timespan, we had to rely on **evidence-based medicine** through testing of a wide array of drugs and empirically building observations to face the medical emergency.

Methodology

- The project was **multidisciplinary** in its approach, involving a wide array of medical specialists

Main findings

- Covid-19 is not merely a lung infection, it is a **systemic disease** which could generate damage in a range of tissues
- Some drugs — especially antivirals and immunomodulatory drugs — are highly effective in containing early-stage infections
- **Only university and research hospitals with multiple specialized units**, working together with experimental units, can effectively develop protocols to manage Covid-19 and carry out innovative therapeutic treatments

Short
term

A diagram consisting of an orange circle on the left containing the text "Short term". A grey arrow points from the right side of this circle towards the "Methodology" and "Main findings" sections of the slide.

...while in the medium-term to fill the Covid-19 scientific vacuum

In the medium-term, the goal is to improve our understanding of Covid-19 pathogenesis and Sars-Cov-2, building on **scientific**, rather than empirical, **observations**

Methodology

- Creation — and analysis — of a **biobank with >2,500 biological samples** from Covid-19 patients
- International consortium with other leading international polyclinics and top scientific institutions

Main findings

- Alongside age and pre-existing pathologies, **genetic predisposition** plays a key role in determining the severity of Covid-19 disease



Medium
term

Improve our understanding of Covid-19 pathogenesis and Sars-Cov-2, thanks to data collected from patients and to the analysis of biobanked samples

GSD hospitals are at the forefront of Covid-19 scientific research

PROGRAM PROJECT COVID-19 KEY NUMBERS

Clinical and experimental
projects



Covid-19 patients
in GSD hospitals

>6,000



Gruppo
San Donato

Scientific publications
(as of Oct. 12th)



310



Biological samples from
Covid-19 patients Biobanked

>2,000



Physicians and experimental
scientists involved (about 50% of
staff)

516

These results were possible only because of the **San Raffaele Model**



The San Raffaele Model

San Raffaele hospital was built based on the Italian IRCCS (***University and Research Hospital***) model, a large (1,000+ bed) multi-specialization facility designed to develop innovative diagnostic and therapeutic approaches by combining:

- Clinic
- Teaching
- Research



The University and Research Hospital model allows for the development of medical and **scientific excellence** in specific areas, and its maintenance over time by **cultivating human capital** through integrated education facilities



An integrated private hospital provides multiple economic and scientific benefits



Economic benefits

- Transparency
- Meritocracy
- Economic efficiency
- Critical mass



Scientific benefits

- Major integrated university and research hospitals can partner with each other to **push the scientific frontier**
- Only facilities with multiple specialized units interacting with each other (**multi-disciplinarity**) can effectively develop — and carry out — therapeutic treatments and research on **systemic diseases, such as Covid-19**

Thank you!



**Gruppo
San Donato**



In collaboration with

**The European House
Ambrosetti**